Drug profile · INN
nintedanib esylate
NINTEDANIB ESYLATE
nintedanib esylate (NINTEDANIB ESYLATE) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — nintedanib esylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
nintedanib esylate (NINTEDANIB ESYLATE) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Fibroblast growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nintedanib esylate?
nintedanib esylate (NINTEDANIB ESYLATE) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nintedanib esylate?
NINTEDANIB ESYLATE is a marketed brand name for nintedanib esylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nintedanib esylate?
nintedanib esylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.